Oxford Biomedica
Result of Annual General Meeting
Oxford, UK -
24 June 2024: Oxford Biomedica plc
(LSE:OXB) ("Oxford Biomedica" or "the Company"), a
quality and innovation-led cell and gene therapy CDMO, today
announces that all resolutions proposed were
duly passed at its Annual General Meeting (AGM), held at 3pm on 24
June 2024 in Oxford. As proposed in the
Notice of AGM, all resolutions were decided by poll
vote.
The full text of all the resolutions can be viewed in
the Notice of Meeting by visiting the Company's website at
www.oxb.com
Copies of the document setting out the above
resolutions passed at the 2024 AGM have been submitted to the
National Storage Mechanism and will shortly be available for
inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism
On the Record Date (20 June 2024) there were
105,268,630 ordinary shares of 50 pence each in issue, each
carrying one vote per share.
|
|
Resolution
|
Votes
For (incl. votes at the
Chairman's discretion)
|
% of votes cast
|
Votes
Against
|
% of votes cast
|
Votes
Withheld*
|
Total
votes cast
|
Result
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary resolutions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1
|
To receive and adopt the Company's
Annual Report and accounts for the financial year ended 31 December
2023, the Directors' Report, and the Report of the Independent
Auditors on those accounts and reports.
|
72,477,617
|
99.99%
|
4,552
|
0.01%
|
608,560
|
72,482,169
|
PASS
|
|
2
|
To receive the Directors'
Remuneration Report and the Report of the Independent Auditors on
the auditable part of the Remuneration Report (excluding the
Directors' Remuneration Policy) for the financial year ended 31
December 2023.
|
72,347,034
|
99.61%
|
280,462
|
0.39%
|
463,233
|
72,627,496
|
PASS
|
|
3
|
To consider and, if thought fit,
approve the Directors' Remuneration Policy, the full text of which
is included in the Directors' Remuneration Report for the financial
year ended 31 December 2023.
|
70,899,498
|
97.67%
|
1,691,080
|
2.33%
|
500,151
|
72,590,578
|
PASS
|
|
4
|
To appoint Peter Soelkner as a
Director of the Company.
|
72,622,493
|
99.98%
|
11,817
|
0.02%
|
456,419
|
72,634,310
|
PASS
|
|
5
|
To reappoint Dr. Roch Doliveux as a
Director of the Company.
|
72,614,517
|
99.97%
|
18,800
|
0.03%
|
457,412
|
72,633,317
|
PASS
|
|
6
|
To reappoint Stuart Henderson as a
Director of the Company.
|
72,621,001
|
99.98%
|
13,309
|
0.02%
|
456,419
|
72,634,310
|
PASS
|
|
7
|
To reappoint Professor Dame Kay
Davies as a Director of the Company.
|
72,619,922
|
99.98%
|
13,395
|
0.02%
|
457,412
|
72,633,317
|
PASS
|
|
8
|
To reappoint Dr. Frank Mathias as a
Director of the Company.
|
72,623,288
|
99.99%
|
10,522
|
0.01%
|
456,919
|
72,633,810
|
PASS
|
|
9
|
To reappoint Stuart Paynter as a
Director of the Company.
|
72,623,118
|
99.99%
|
10,199
|
0.01%
|
457,412
|
72,633,317
|
PASS
|
|
10
|
To reappoint Robert Ghenchev as a
Director of the Company.
|
72,585,321
|
99.93%
|
47,996
|
0.07%
|
457,412
|
72,633,317
|
PASS
|
|
11
|
To reappoint Namrata Patel as a
Director of the Company.
|
72,619,735
|
99.98%
|
13,582
|
0.02%
|
457,412
|
72,633,317
|
PASS
|
|
12
|
To reappoint
Leone Patterson as a Director of the
Company.
|
71,427,129
|
98.34%
|
1,206,006
|
1.66%
|
457,594
|
72,633,135
|
PASS
|
|
13
|
To reappoint Dr. Heather Preston as a
Director of the Company.
|
71,207,370
|
98.04%
|
1,425,964
|
1.96%
|
457,395
|
72,633,334
|
PASS
|
|
14
|
To appoint PricewaterhouseCoopers LLP
as auditors of the Company from the conclusion of the meeting until
the conclusion of the next AGM of the Company at which the accounts
are laid.
|
72,579,009
|
99.98%
|
16,159
|
0.02%
|
495,561
|
72,595,168
|
PASS
|
|
15
|
To authorise the Audit Committee for
and on behalf of the Board to determine the auditor's
remuneration.
|
72,580,492
|
99.98%
|
15,389
|
0.02%
|
494,848
|
72,595,881
|
PASS
|
|
16
|
To approve the Oxford Biomedica 2024
Long Term Incentive Plan.
|
62,538,002
|
86.10%
|
10,095,007
|
13.90%
|
457,720
|
72,633,009
|
PASS
|
|
17
|
To approve the Oxford Biomedica 2024
Deferred Bonus Plan.
|
62,775,222
|
86.43%
|
9,856,415
|
13.57%
|
459,092
|
72,631,637
|
PASS
|
|
18
|
To approve the Oxford Biomedica 2024
Sharesave Scheme.
|
63,225,470
|
87.05%
|
9,408,593
|
12.95%
|
456,666
|
72,634,063
|
PASS
|
|
19
|
To authorise the Directors to allot
shares.
|
72,168,633
|
99.41%
|
426,961
|
0.59%
|
495,135
|
72,595,594
|
PASS
|
|
20
|
To authorise the Directors to
disapply pre-emption rights.
|
72,215,940
|
99.48%
|
378,341
|
0.52%
|
496,448
|
72,594,281
|
PASS
|
|
21
|
To authorise the Directors to further
disapply pre-emption rights for acquisitions and specified capital
investments.
|
72,215,440
|
99.48%
|
378,841
|
0.52%
|
496,448
|
72,594,281
|
PASS
|
|
22
|
To permit the Directors to convene
general meetings (other than annual general meetings) on not less
than 14 days' notice.
|
72,369,632
|
99.63%
|
265,377
|
0.37%
|
455,720
|
72,635,009
|
PASS
|
* A vote withheld is not a vote in
law and is not counted towards votes cast in respect of a
resolution.
In addition, further to the
announcement by the Company on 11 March 2024, Dr. Michael Hayden
and Catherine Moukheibir have stepped down from the Company's Board
of Directors with effect from the conclusion of today's
AGM.
-Ends-
|
For further
information, please contact:
|
|
|
Oxford
Biomedica plc:
Natalie Walter, Company Secretary
|
Tel: +44 (0)1865 783 000
|
ABOUT OXFORD
BIOMEDICA
Oxford Biomedica (LSE: OXB) is a quality and
innovation-led contract development and manufacturing organisation
(CDMO) in cell and gene therapy with a mission to enable its
clients to deliver life changing therapies to patients around the
world.
One of the original pioneers in cell and gene
therapy, OXB has more than 25 years of experience in viral vectors;
the driving force behind the majority of cell and gene therapies.
OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV), adenovirus, and other viral vector
types. Oxford Biomedica's world-class capabilities span from
early-stage development to commercialisation. These capabilities
are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is
headquartered in Oxford, UK. It has
bioprocessing and manufacturing facilities across Oxfordshire, UK,
Lyon and Strasbourg, France, and near Boston, MA, US. Learn more
at www.oxb.com, and follow us on
LinkedIn
and YouTube.
